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Abstract
• Management of type 2 diabetes mellitus (T2DM) is focused on
strict glycemic control in order to prevent complications.
• Currently, self-monitoring of blood glucose (SMBG) with
fingerstick blood sample is the conventional method to assess
short-term glycemic control.
• Due to several limitations of SMBG, continuous glucose
monitoring (CGM) is emerging as a potential replacement for
SMBG in patients with type 2 diabetes.
• Therefore, this study examines whether CGM leads to greater
improvement in glycemic control compared to SMBG in
nonpregnant adults with T2DM.

Introduction
• In the U.S., 34.1 million adults (age ≥18 years) or 13% of the adult
population are diagnosed with T2DM.1
• Prevalence of T2DM is the lowest in non-Hispanic whites, higher in
Asians and Hispanics, and the highest in African Americans.1
• Effective glycemic control is integral to diabetes management in
order to lower the risk of complications such as retinopathy,
neuropathy, cardiovascular disease and renal disease.2,3
• SMBG with fingerstick blood sample has traditionally been used to
monitor short-term glycemic control. However, several barriers
limit its use, such as discomfort, inconvenience, and high costs.3-6
• CGM technology uses subcutaneously inserted sensors to measure
real-time interstitial glucose levels throughout the day, providing
convenience, ease of use and data shareability at lower costs.7-9
• Currently, CGM is the gold standard of care for adults with type 1
diabetes (T1DM) and used less frequently in those with T2DM.3
• Several studies have shown mixed results regarding whether CGM
improves glycemic control in patients with T2DM.10, 11
• Therefore, more research is needed to determine the
effectiveness and optimal uses of CGM in patients with T2DM.

Methods
• A literature search was performed in November 2019 using
PubMed, Academic Search Ultimate, and Google Scholar.
• Search terms used were "type 2 diabetes OR type 2 diabetes
mellitus AND continuous glucose monitoring OR CGM”.
• Inclusion and exclusion criteria were manually applied for study
selection. Any duplicate studies were removed.
• Randomized control trials, cohort studies, or case-control studies
with sample size >100, published in 2014 or later were considered.
• This left a final set of 7 articles for critical appraisal.

Results

Discussion

All 7 studies differed in the glycemic parameter affected by CGM use, as shown in Table
1. However, at least 1 variable was shown to be significantly associated with the CGM
use in each of the studies. Notably, the study by Anjana et al. showed that a single
CGM wear lasting 14 days was enough to produce a clinically meaningful change in
HbA1c at 3 months. Also, the greatest improvement in glycemic control was seen in
participants using multiple dose insulin (MDI) injections and in those with baseline
hyperglycemia of >240 mg/dL, according to the studies by Ajjan et al. and Ruedy et al.
However, New et al. found that the CGM group with continuous subcutaneous insulin
infusion (CSII) had a significantly improved glycemic control, while those with MDI did
not. In the study by Ajjan et al., healthcare providers reported that CGM data aided
their communication with patients and treatment adjustments. Also, multiple studies
showed that advanced age did not appear to be a barrier to using CGM devices.

6/6 studies report that at least 1 glycemic parameter was
significantly improved in CGM group compared to SMBG group.

Other findings associated with CGM use
• HbA1c (long-term glycemic control): significant improvement in 4/6 studies
• Diabetes treatment satisfaction: significant improvement in 4/4 studies
• Diabetes quality of life: significant improvement in 2/3 studies

Strengths:
v Diverse clinical settings and countries
v Most (5/7) were randomized control trials
v Study duration of at least 2-3 months
v Sample size of at least 100 participants
Weaknesses:
v Lack of demographic diversity in participant pool (most were
non-Hispanic whites in their 60s)
v Lack of blinding
v Potential for sponsorship bias and observer bias

SMBG

CGM

Table 1. Comparison of Results

Time in
glucose
range
Study

Hypoglycemia
<55 mg/dL

<70 mg/dL

Ajjan et al
(2019)

N/A

NS

Anjana et al
(2017)

N/A

Euglycemia

Hyperglycemia

70-180 mg/dL >180 mg/dL

NSa

NS

>240 mg/dL

NS
Note: Images adapted from https://www.hcd.com

N/A

N/A

N/A

N/A

Haak et al
(2016)

S

S

NS

NS

NS

Jangam et al
(2019)

Sa

Sa

N/A

Sa

Sa

New et al
(2015)

N/A

Sb

NS

N/A

N/A

Ruedy et al
(2017)

N/A

N/A

S

N/A

S

Yaron et al
(2019)

N/A

N/A

N/A

N/A

N/A

Key
S = significant improvement compared to control (p ≤ 0.05)
NS = not significant improvement compared to control (p > 0.05)
N/A = not available
a=Results were compared to baseline values instead of control values.
b=Result was significant in the intervention group that utilized CGM with alarms, while it was insignificant in the intervention group without alarms.

Conclusion
• The findings of the 7 studies collectively suggest that CGM may be
beneficial in improving glycemic control, particularly in patients
with insulin-treated T2DM.
• CGM can potentially be a useful tool in guiding treatment
decisions including insulin dose adjustments as well as in serving
as a basis for patient education and counseling.
• Limited and variable evidence for benefits of CGM in T2DM
warrants further focused research in this topic.
• Future studies should involve more accurately represented
demographics in participant pool and independent, third-party
researchers to reduce potential sponsorship bias.
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